The present study confirms that CDK4/6 inhibitors provide clinical benefits, including OS benefit consistent with PFS, to HR+/HER2- advanced breast cancer patients (Figs. 2 and 5A). The gene discussed is ERBB2; the disease is breast carcinoma.